Mergers & AcquisitionsBy The Online Investor Staff, updated Wed., Feb. 26, 4:35 PM
|This Slide: #30 of 100|
Slide #30. Tocagen Inc. — Forte Biosciences, Inc.
Tocagen Inc. (NASDAQ:TOCA)
Forte Biosciences, Inc.
Tocagen Inc. (Nasdaq: TOCA), and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced today that they have entered into a definitive agreement under which Tocagen will merge with Forte in an all-stock transaction. The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis. Upon stockholder approval, the combined company is expected to operate under the name Forte Biosciences and trade on the Nasdaq Capital Market under the ticker symbol FBRX.
Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing product candidates designed to activate a patient's immune system against their own cancer. Co. is developing its primary product candidate, Toca 511 (vocimagene amiretrorepvec) and Toca FC (extended-release flucytosine), for the treatment of recurrent high grade glioma, a brain cancer with limited treatment options, low survival rates and, therefore, an unmet medical need. In addition, Co. is developing other retroviral replicating vectors to deliver genes to cancer cells against validated immunotherapy targets.
TOCA SEC Filing Email Alerts Service
Open the TOCA Page at The Online Investor »
Hold (2.00 out of 4)
(ranked lower than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite